Vitamin K1 (Phylloquinone) and arterial calcification

What 2 graded rows on vitamin k1 (phylloquinone) agree on for arterial calcification, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Vitamin K1 (Phylloquinone) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Vitamin K1 (Phylloquinone) page, with its PubMed record.

Supplement

Vitamin K1 (Phylloquinone) Choose another

2 rows · 457 people

They agree: both rows found no difference.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade C, is a randomized trial of 388 people (2009) and found no difference.

The rows run from 69 to 388 people, published from 2009 to 2023: 2 single studies.

2 no difference

Grade CCoronary artery calcium progression · No difference
RCT · n 388 · 2009 · Healthy older men and postmenopausal women
500 mcg/day vs multivitamin alone · 3 years
No difference in calcium-score progression by intention to treat (mean change 27 vs 37 Agatston units). In adherent participants and in those with existing calcification, progression was smaller on phylloquinone; the authors call this hypothesis-generating.
Row on the Vitamin K1 (Phylloquinone) page · PubMed 19386744 (opens PubMed)
Grade DCoronary artery calcium progression in people on hemodialysis · No difference
Pilot RCT · n 69 · 2023 · Adults on hemodialysis with a coronary calcium score of 30 or more (iPACK-HD, Canada; 86 randomised)
10 mg three times a week · 12 months
Phylloquinone cut dephospho-uncarboxylated MGP by 86% and raised K1 levels and the carboxylated-to-uncarboxylated osteocalcin ratio versus placebo, but coronary calcification progressed no differently between groups.
Row on the Vitamin K1 (Phylloquinone) page · PubMed 35641194 (opens PubMed)